TESAMORELIN
For Research Use Only | Not for Human or Veterinary Use
Reconstitution Warning: For best results, use only Hospira® Bacteriostatic Water or ezPeps Bacteriostatic Water. Tesamorelin is highly sensitive to diluent composition, and use of saline, bacteriostatic sodium chloride, or other non-recommended products may cause gelling or precipitation. Issues resulting from non-recommended diluents are not eligible for refund, replacement, or credit.
Description:
Tesamorelin is a synthetic 44-amino acid peptide analogue of human growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group at the N-terminus to enhance metabolic stability and receptor binding affinity. In preclinical laboratory research, Tesamorelin is investigated as a GHRH receptor agonist that stimulates pulsatile growth hormone (GH) release from anterior pituitary somatotrophs. The trans-3-hexenoic acid modification distinguishes Tesamorelin from native GHRH(1–44) and the truncated analogue Sermorelin (GRF 1–29), conferring improved resistance to dipeptidyl peptidase IV (DPP-IV) cleavage. Tesamorelin serves as a research tool in neuroendocrinology, GH axis regulation, and metabolic pathway studies involving growth hormone-dependent lipid metabolism.
Scientific Specifications:
- Peptide Name: Tesamorelin (trans-3-hexenoic acid-GHRH(1–44))
- Type: Synthetic 44-Amino Acid Peptide (Modified GHRH Analogue)
- Sequence: (trans-3-hexenoic acid)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
- Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
- Molecular Weight: 5135.86 g/mol
- CAS Number: 218949-48-5
- PubChem CID: 16137828
- Form: Lyophilized powder
- Storage: Store dry in a cool, dark environment (2°C to 8°C)
Research Context:
Tesamorelin is commonly studied for its potential effects on:
- GHRH receptor agonism and pulsatile growth hormone secretion stimulation
- Visceral adipose tissue metabolism and GH-dependent lipolytic pathway activation
- IGF-1 axis regulation and downstream somatomedin-mediated signaling
- DPP-IV resistance and enhanced pharmacokinetic stability of modified GHRH analogues
- Hepatic lipid metabolism and triglyceride accumulation in metabolic research models
- Comparative pharmacology with Sermorelin and native GHRH(1–44) at the GHRH receptor
Intended Use:
This product is intended strictly for
laboratory research applications only by qualified scientific personnel. It is not approved for human or animal consumption, and may not be used in foods, drugs, supplements, cosmetics, or diagnostics.
Legal Disclaimer:
The statements provided and this compound have not been evaluated by the U.S. Food and Drug Administration. No claims are made regarding diagnosis, treatment, or prevention of any disease. Use is restricted to qualified researchers operating in certified laboratory environments.
Terms of Sale:
By purchasing this product, the buyer affirms they are a qualified researcher or institutional purchaser, fully responsible for proper handling, storage, and legal compliance.